Speaker Profile
Senior Managing Director, Blackstone Life Sciences
Biography
Mr. Simon has over 30 years of operating and investment experience in the healthcare sector, and has led investments in biotechnology, pharmaceutical company partnerships, and medical technology. Prior to Clarus, Mr. Simon was a General Partner at MPM Capital, a healthcare venture capital firm. Prior to MPM Capital he was with Genentech from 1989 to 2000 where he was Vice President of Business and Corporate Development. Mr. Simon is currrently serving on the Board of Directors of Gritstone Oncology (NASDAQ: GRTS), Lycera, Nuvelution Pharma, Inc. and Sientra (NASDAQ:SIEN). Mr. Simon is a Trustee at The J David Gladstone Institutes, a private not-for-profit research institute affiliated with the University of California, San Francisco.
Session Abstract – PMWC 2020 Silicon Valley
This panel will discuss the status quo on VC investment in Cardiovascular Disease. Panelists will explore how new preclinical discovery paradigms, the use of personalized medicine approaches (i.e. biomarkers for patient stratification and trial acceleration) and novel therapeutic modalities could change the trajectory of VC investment in the Cardiovascular Space.
